Cambium Bio Secures Funding to Advance Dry Eye Disease Treatment

Cambium Bio Limited, a clinical-stage regenerative medicine company, announced that it has successfully completed an A$3.0 million capital raising round. This funding will primarily support the development of Elate Ocular, a novel treatment for dry eye disease (DED), through registration-enabling Phase 3 clinical trials.

Funding Details

The capital raise, approved by shareholders, is composed of:

       • A$1.5 million strategic investment from AventaCell Biomedical Corp.

       • A$0.25 million investment from Zheng Yang Biomedical Technology.

       • A$0.146 million from Cambium Bio directors.

       • A$1.054 million from Cambium Bio’s CEO, Australian institutions, and sophisticated investors.

Advancing Elate Ocular

Elate Ocular is a groundbreaking treatment derived from enriched fibrinogen-depleted human platelet lysate. Key features include:

       • A pH and osmolarity similar to normal tears.

       • A higher overall protein content compared to natural tears.

The therapy is designed to address the underlying causes of dry eye disease, a condition affecting millions globally.

Clinical Trial History

In 2020, Cambium Bio conducted a clinical trial for Elate Ocular involving 64 adults across nine sites in the United States.

       • Study Design: Double-blind, 1:1:1 randomization to vehicle, 10%, and 30% Elate Ocular.

       • Primary Endpoints: Safety and tolerability.

       • Secondary Endpoints: Changes in ocular signs and symptoms on day 42.

       • Results: The trial met all safety and tolerability endpoints, demonstrating the potential of Elate Ocular as a safe and effective treatment.

Upcoming Phase 3 Trials

Cambium Bio plans to initiate two Phase 3 clinical trials for Elate Ocular, titled Camomile-2 and Camomile-3, in April 2025, with results anticipated by mid-2026. These trials aim to further validate the therapy's efficacy and pave the way for regulatory approval.

A Step Toward Innovative Dry Eye Solutions

With this latest funding round, Cambium Bio is well-positioned to advance Elate Ocular, offering new hope for patients suffering from dry eye disease. The company’s commitment to innovative, regenerative treatments could redefine the future of eye care.